FIELD: medicine.
SUBSTANCE: group of inventions relate to method for prevention and/or treatment, and/or limitation of aggravation of knee joint osteoarthritis in human, including introduction of pharmaceutical composition, which contains parathyroid hormone (PTH) or PTH derivative as active ingredient, with effective dose of PTH or PTH derivative constituting 100-200 units per week. Group of inventions also deals with method for prevention and/or treatment, and/or limitation of aggravation of knee joint osteoarthrosis in human, accompanied by osteoporosis.
EFFECT: considerable reduction of frequency of osteoarthritis development and osteoarthrosis treatment efficiency.
6 cl, 2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PTH-CONTAINING THERAPEUTIC/PROPHILACTIC ANTI-OSTEOPOROSIS AGENT, CHARACTERISED BY WEEKLY INTRODUCTION OF PTH IN STANDARD DOSE OF 100-200 UNITS | 2010 |
|
RU2564894C2 |
| METHOD OF TREATING KNEE OSTEOARTHRITIS | 2024 |
|
RU2822321C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING HYDANTOIN DERIVATIVES | 2014 |
|
RU2701168C2 |
| OSTEOARTHRITIS TREATMENT | 2006 |
|
RU2385157C1 |
| MONTELUKAST FOR TREATMENT OF EROSIVE OSTEOARTHRITIS OF THE HAND | 2019 |
|
RU2809024C2 |
| APPLICATION OF SOPHORICOSIDE FOR PREPARING DRUGS | 2009 |
|
RU2454236C1 |
| METHOD FOR SURGICAL MANAGEMENT OF MEDIAL OSTEOARTHRITIS OF KNEE JOINT | 2023 |
|
RU2816801C1 |
| PHARMACEUTICAL COMPOSITION FOR SAFE AND EFFECTIVE TREATMENT OF KNEE AND/OR HIP JOINT PAIN | 2019 |
|
RU2786232C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING JOINT AND BONE TISSUE DISEASES | 2013 |
|
RU2547572C2 |
| C1 PROTEIN 2 CHAIN OF CARTILAGE INTERMEDIATE LAYER AND USE THEREOF FOR DIFFERENTIAL DIAGNOSIS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS AND NON-PATHOLOGICAL STATES | 2008 |
|
RU2481586C2 |
